PSG announces the results of the industry’s go-to report on specialty drug spend and trend.
With specialty drug costs remaining a top concern and a pipeline bursting with breakthrough therapies, payers can’t afford to manage specialty spend with yesterday’s strategies. The 2026 Artemetrx State of Specialty Spend and Trend Report delivers the critical data you need to stay ahead of the curve.
Key Findings
- Specialty Drug Trend: Specialty drug trend remains high but decreased from 12.2% to 10.8% on a gross cost basis
- Drivers of Specialty Drug Trend: Claim utilization is now the dominant driver of specialty drug trend as the percentage of members using specialty drugs rose to 5.5%
- Top Specialty Drugs by Spend: Humira exited the top 10 specialty drugs by spend as Skyrizi, Dupixent, and Rinvoq climbed up the list
- Biosimilars Market Share: The market share for biosimilars grew from 32.2% to 56.3%, led by the impact of Humira and Stelara biosimilars
- Non-Specialty Drug Spend and Trend: Spotlight feature reveals 10.4% trend in non-specialty, driven by the diabetes category and GLP-1 medications
